TICKERNERD
Menu
XNCRXNCRHealthcare · Biotechnology

XNCR Stock Forecast: Xencor, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$30
+2.09% on the day

The 14 Wall Street analysts covering Xencor, Inc. hold a median 12-month price target of $42 — +40.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
85/ 100
Median analyst target
$42
Analysts covering
14
Revenue$51.2M+17.5% y/y
Operating income−$37.1M
Net income−$21.7M
Free cash flow−$56.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+18.4%
1M
+19.5%
YTD
+94.8%
1Y
+111.0%
From 52W high
−0.6%
From 52W low
+186.5%
$10
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XNCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xencor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
85/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Revisions
80
Issuance
74
Volatility
74
Value
69
Quality
64
Accruals
58
Growth
35
Size
33

Momentum (98): The shares have been drifting up relative to others.

Growth (35): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XNCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XNCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26XNCRHigh $70Median $42Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $21Median $42High $70

The green dot is the last close — the median target sits +40.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
27 Oct 2026RBC CapitalMaintainsOutperform$20 → $43
27 Oct 2026Truist SecuritiesMaintainsBuy$29 → $40
27 Oct 2026WedbushMaintainsOutperform$30 → $45
27 Oct 2026Wells FargoMaintainsOverweight$30 → $44
21 Oct 2026WedbushReiteratesOutperform$30
28 Sept 2026Truist SecuritiesReiteratesBuy$27 → $29
28 Sept 2026Truist SecuritiesReiteratesBuy—
21 Sept 2026B of A SecuritiesMaintainsNeutral$20 → $26
21 Sept 2026B of A SecuritiesMaintainsNeutral—
11 Sept 2026BarclaysMaintainsOverweight—
11 Sept 2026BarclaysMaintainsOverweight$27 → $35
3 Sept 2026JP MorganMaintainsNeutral—
3 Sept 2026JP MorganMaintainsNeutral$14 → $21
1 Sept 2026Raymond JamesMaintainsStrong Buy—
1 Sept 2026Raymond JamesMaintainsStrong Buy$40 → $46
6 Aug 2026Cantor FitzgeraldMaintainsOverweight—
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$43 → $44
6 Aug 2026RBC CapitalMaintainsOutperform$19 → $20
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XNCR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XNCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Xencor, Inc. returned +111.0% against +12.4% for the S&P 500, dividends included.

XNCR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26XNCRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XNCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
9
Analysts cutting
2
Fundamentals

Xencor, Inc. (XNCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−24.0×

Cheaper than 97% of US stocks

Price / sales
21.1×

Cheaper than 8% of US stocks

Price / book
4.4×

Cheaper than 21% of US stocks

EV / EBITDA
−9.4×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
17.5%

Higher than 66% of US stocks

Earnings growth (YoY)
17.5%

Higher than 56% of US stocks

Gross margin
—
Operating margin
−72.4%

Higher than 15% of US stocks

Net margin
−155.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−29.1%

Higher than 27% of US stocks

Return on assets
−16.8%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xencor, Inc. (XNCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xencor, Inc. has a market value of $2.2B and an enterprise value of $1.9B.

  • Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 17.5% year on year.

  • Net income over the same four quarters: −$163.3M, a −155.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.17.

  • Free cash flow in the twelve months to 30 June 2026: −$208.3M.

  • Shares outstanding: 74.3M.

  • Trailing P/E: −24.0×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Xencor, Inc. employs 260 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

XNCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XNCRXencor, Inc.$2.2B85
AUPHAurinia Pharmaceuticals, Inc.$2.2B98
HRMYHarmony Biosciences Holdings, Inc.$2.2B84
BHVNBiohaven Ltd.$2.2B53
VERAVera Therapeutics, Inc.$2.2B27
IMNMImmunome, Inc.$2.1B31
NAMSNewAmsterdam Pharma Co. NV$2.3B46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xencor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XNCR news & analysis

Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway

Seeking Alpha · 26 Oct 2026positive

The Seeking Alpha item reports positive phase 1 dose-expansion results for Xencor’s XmAb819 in advanced ccRCC, including a 45.5% cORR at 400 mcg/kg. It says the company plans pivotal phase 3 development and expects to discuss a potential FDA Accelerated Approval pathway in 1H 2027.

Why it matters — The results and stated development plans provide updates on XmAb819’s progress, alongside Xencor’s expansion of the program into other ENPP3+ solid tumors and continued XmAb942 development.

Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer

MarketBeat · 26 Oct 2026positive

Xencor reported updated Phase 1 dose-expansion results for XmAb819 in previously treated advanced clear cell renal cell carcinoma at ESMO 2026. It selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.

Why it matters — The update provides XNCR watchers with a selected dose and anticipated timeline for further development of XmAb819.

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

Benzinga · 26 Oct 2026neutral

At the ESMO Congress 2026, Xencor shared updated Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma. The excerpt does not provide the results’ details.

Why it matters — The update concerns an early-stage Xencor drug study, though the excerpt does not describe the findings or their implications.

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

Business Wire · 25 Oct 2026neutral

Xencor announced updated Phase 1 results for XmAb819, an ENPP3 x CD3 T-cell-engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. The data were presented by Sumanta Pal of City of Hope.

Why it matters — The update concerns clinical development of Xencor’s XmAb819 candidate for advanced ccRCC and ENPP3-positive tumors.

FAQ

Frequently asked questions about XNCR stock

What is the XNCR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Xencor, Inc. have a median 12-month price target of $42, with estimates ranging from $21 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XNCR stock a buy right now?

Of the 14 analysts covering Xencor, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xencor, Inc. 85 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XNCR?

As at 31 Oct 2026, Xencor, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will XNCR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +40.8% from the last close, and Ticker Nerd's factor model ranks Xencor, Inc. 85 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XNCR stock forecast for 2030?

No analyst covering Xencor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XNCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $70 over the next 12 months.

How has XNCR stock performed over the past year?

Xencor, Inc. returned +111.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xencor, Inc. do?

Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases.

What is the latest news on XNCR?

The most recent item we track (Seeking Alpha, 26 Oct 2026): "Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway". The Seeking Alpha item reports positive phase 1 dose-expansion results for Xencor’s XmAb819 in advanced ccRCC, including a 45.5% cORR at 400 mcg/kg. It says the company plans pivotal phase 3 development and expects to discuss a potential FDA Accelerated Approval pathway in 1H 2027.

Company

About Xencor, Inc.

Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to create next-generation antibodies and bispecific molecules with tailored biological activity, supporting a portfolio of proprietary and partnered programs in clinical development. Xencor’s work centers on protein engineering that can improve how therapies interact with immune targets and disease pathways, making it a specialized participant in modern antibody drug innovation. The company also collaborates with external partners to apply its platform across multiple therapeutic areas, including oncology and immunology. Headquartered in Pasadena, California, Xencor Inc. operates as a biotechnology company whose current business is built around research, development, and collaboration in advanced biologic medicines.

CEO Dr. Bassil I. Dahiyat Ph.D. · 260 employees · United States · https://www.xencor.com